Trials / Completed
CompletedNCT03687073
Trial of Indole-3-Carbinol and Silibinin
Trial of Indole-3-Carbinol & Silibinin
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a non-therapeutic, Phase 1 clinical trial to examine the safety, pharmacokinetic (PK) characteristics, and pharmacodynamics (PD) effect of indole-3-carbinol (I3C) and silibinin (Sil) in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Indole-3-Carbinol | Cohorts 2, 3, \& 4: 400 mg PO BID |
| DRUG | Silibinin | Cohorts 1 \& 4: 720mg |
| DRUG | Silibin | Cohort 3: 360mg |
Timeline
- Start date
- 2018-11-29
- Primary completion
- 2021-05-07
- Completion
- 2021-05-07
- First posted
- 2018-09-27
- Last updated
- 2021-08-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03687073. Inclusion in this directory is not an endorsement.